
A new immunotherapy treatment for aggressive stomach cancer has been approved by the NHS spending watchdog.
The National Institute for Health and Care Excellence (Nice) has given the green light for the immunotherapy drug durvalumab, also known as Imfinzi and made by AstraZeneca, to be used by the NHS for adults whose stomach cancer has not spread extensively and can be surgically removed.